Jinwon Life Sciences Signs $2.3 Million Plasmid DNA Drug Supply Contract

[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 18th that it has signed a plasmid DNA pharmaceutical supply contract worth $2.3 million with a U.S. gene therapy company. The contracting party has not been disclosed according to the contract, and the total contract amount is approximately 2.5 billion KRW when converted to Korean won.

Park Young-geun, CEO of GeneOne Life Science, stated, “Every year, around 200 early-stage cell and gene therapy clinical trial applications (IND) are submitted to the U.S. FDA. Since there is a risk of delays in research and development if plasmid DNA is not supplied on time, requests for supply from our company, which produces high-quality plasmid DNA pharmaceuticals, have increased significantly.”

Meanwhile, GeneOne Life Science produces and supplies high-quality plasmid DNA pharmaceuticals through its subsidiary VGXI, a contract development and manufacturing organization (CDMO) specializing in current Good Manufacturing Practice (cGMP) pharmaceuticals.

This content was produced with the assistance of AI translation services.